Cumberland Pharmaceuticals Inc

Cumberland Pharmaceuticals Inc has a market capitalization of $73.72 million and a price-to-book ratio of 2.8, indicating a premium valuation relative to its book value. The company holds $17.34 million in cash and equivalents, while its total liabilities amount to $52.17 million, resulting in a debt-to-equity ratio of 0.61. The current ratio of 1.44 suggests moderate liquidity, but the negative operating cash flow of -$2.99 million and free cash flow of -$9,990 indicate ongoing cash flow challenges.

Profitability metrics show a significant decline in performance. The company reported a net loss of $1.09 million and an operating loss of $1.03 million, with a return on equity of -4.12% and a return on assets of -1.38%. These figures are below the industry median for profitability, as the pharmaceutical sector typically exhibits higher returns due to strong pricing power and R&D productivity.

Geographically and segment-wise, Cumberland Pharmaceuticals Inc does not disclose detailed revenue breakdowns in the latest financials. However, the company's product portfolio is concentrated in gastrointestinal and pain management therapies, which are core to its business model. The lack of geographic diversification and segment-specific data suggests a high degree of revenue concentration in a few therapeutic areas, which could pose risks in the event of regulatory or market shifts.

Looking ahead, the company is expected to face continued financial pressure. The operating income is projected to remain negative, and the net loss is likely to persist. The capital expenditure of -$104,990 indicates minimal investment in growth, which may limit future revenue expansion. The absence of analyst buy or strong-buy ratings further signals a cautious outlook from the market.

Risk factors include liquidity constraints and the potential for dilution, although the risk assessment indicates both are currently low. The company has no immediate filing-based liquidity or dilution flags, but the negative operating cash flow and low analyst sentiment suggest ongoing financial stress. The dilution potential is also low, with no recent issuance or shelf registration activity reported.

Recent events include the latest financial filing, which highlights the company's continued losses and cash flow challenges. No significant regulatory or legal events were disclosed in the latest reports, but the company's reliance on a narrow product portfolio and therapeutic focus may expose it to market volatility. The lack of recent positive developments or strategic announcements further supports the cautious outlook.

Revenue grew 17.6% year-over-year to $44.5 million, demonstrating strong top-line expansion momentum.

Free cash flow turned positive at $1.1 million, marking a 164.6% improvement from the prior year.

Net income improved by 56.2% year-over-year, signaling significant progress toward profitability despite remaining losses.

Cash conversion ratio of 2.76 ranks as best-in-class compared to the pharmaceutical cohort median.

Long-term debt decreased to $5.2 million, reducing leverage from $15.3 million in the prior period.

Credit risk is flagged as high, reflecting significant financial vulnerability despite recent cash flow improvements.

Return on equity is negative at -4.1%, underperforming the cohort median of 2.9% significantly.

Debt-to-equity ratio stands at 2.10, placing the company in the bottom quartile for leverage within its cohort.

Revenue $36.0M; Operating income -$7.7M.

• ▍Revenue $36.0M
• ▍Operating income -$7.7M
• ▍Net margin -9.7%